Antidepressant prescribing in Irish children: secular trends and international comparison in the context of a safety warning

K. O’Sullivan1*, F. Boland1, U. Reulbach1,2, N. Motterlini1, D. Kelly2, K. Bennett3 and T. Fahey1

Abstract

Background: In 2003, the Irish Medicines Board (IMB) warned against the treatment of childhood depression with selective serotonin reuptake inhibitors (SSRIs) due to increased risk of suicide. This study examined the effect of this warning on the prevalence of anti-depressants in Irish children and compared age and gender trends and international comparisons of prescription rates.

Methods: A retrospective cohort study of the Irish Health Service Executive (HSE) pharmacy claims database for the General Medical Services (GMS) scheme for dispensed medication. Data were obtained for 2002–2011 for those aged ≤15 years. Prevalence of anti-depressants per 1000 eligible population, along with 95 % confidence intervals, were calculated. A negative binomial regression analysis was used to investigate trends and compare rates across years, sex and age groups (0–4, 5–11, 12–15 years). International prescribing data were retrieved from the literature.

Results: The prevalence of anti-depressants decreased from 4.74/1000 population (95 % CI: 4.47-5.01) in 2002 to 2.61/1000 population (95 % CI: 2.43-2.80) in 2008. SSRI rates decreased from 2002 to 2008. Prescription rates for contra-indicated SSRIs paroxetine, sertraline and citalopram decreased significantly from 2002 to 2005, and, apart from paroxetine, only small fluctuations were seen from 2005 onwards. Fluoxetine was the most frequently prescribed anti-depressant and rates increased between 2002 and 2011. Anti-depressant rates were higher for younger boys and older girls. The Irish prevalence was lower than the US, similar to the U.K. and higher than Germany and Denmark.

Conclusions: The direction and timing of these trends suggest that medical practitioners followed the IMB advice.

Keywords: Children, Anti-depressants, Paediatric prescribing, Safety warning
depression and drug trials that showed the ineffectiveness of tricyclic anti-depressants in the treatment of childhood depression [3]. Further support for their use in childhood depression and anxiety came from early randomised controlled trials (RCT) which showed high levels of SSRI efficacy in comparison to placebo [7, 10, 11]. However, reviews of SSRI safety and efficacy in the treatment of childhood depression later revealed they were more harmful than what had been originally reported [12, 13].

In 2003, the Food and Drug Administration (FDA) requested that GlaxoSmithKline (GSK) provide the results of all drug trials that had examined the efficacy of SSRIs in the treatment of Major Depressive Disorder (MDD) in children. This request followed the airing of a documentary which highlighted the side effects of Seroxat (paroxetine) and the suppression of data reporting these side effects by the pharmaceutical industry. In May 2003, the GSK report revealed an association with paroxetine and suicidal behaviour in children. Following this, and other reports the FDA published an advisory paper highlighting the increased risk of suicidal behaviour in children being treated with SSRIs. Later that year, the Medicines and Health Regulatory Agency (MHRA) issued a recommendation to withdraw the use of all SSRIs in children with MDD, except for fluoxetine [12], a move which was endorsed by the Irish Medical Board (IMB). In late 2004, the FDA required that manufacturers add a black box warning to all SSRIs including the risk of suicidal behaviours [13]. The SSRIs paroxetine, sertraline and citalopram were contraindicated in children for the treatment of depression following these warnings. Since 2004 these warnings have been extended, the FDA increased the age bracket from 18 to 24 in 2007 and the IMB adapted the SSRI warning up to the age of 25 in 2008 (see Table 1) [14].

Increased rates in psychotropic drug prescribing in children have been reported in recent times [15–19], and anti-depressants are often the most frequently prescribed [15–17]. While studies have shown that prevalence of anti-depressants declined immediately following the introduction of the FDA boxed warnings [6, 20], there is evidence to suggest that this decline was not sustained and that the prevalence of paediatric anti-depressant prescribing is on the rise [21]. Furthermore, there is wide variability across countries in the use of anti-depressant medication for children. For example, in 2000 in the US, the prevalence was 15 times greater than that of Germany, and the rate in Germany was 9 times greater than that in Denmark [9]. These differences are thought to be due to several factors; including differences in diagnostic criteria, treatment guidelines, drug regulations and healthcare systems [9].

The aims of the current study are (i) to examine whether the introduction of the IMB warnings was associated with a reduction in overall and specific prevalence of anti-depressants in Irish children, and (ii) to establish whether the effect of this warning was maintained. Age and gender trends were also considered, and additionally, the prevalence of anti-depressants in children in Ireland was compared to international studies.

**Methods**

**Study population and study design**

Data was obtained from the Irish General Medical Services (GMS) scheme pharmacy claims database from the Health Service Executive (HSE) – Primary Care

| Year, Month | Country | Agency | Action |
|-------------|---------|--------|--------|
| 2003, May   | -       | GSK    | Reported to FDA increased suicidal behaviour associated with paroxetine |
| 2003, June  | U.K.    | MHRAa  | Paroxetine contraindicated in <18 s |
| 2003, September | U.K. | MHRA  | Venlafaxine contraindicated in <18 s |
| 2003, October | U.S.   | FDAb   | Advice paper published stating preliminary data suggests increased suicidal behaviour associated with SSRIs |
| 2003, December | U.K. | MHRA  | Contraindicate all SSRIs in <18 s apart from Prozac (fluoxetine) |
| 2003, December | Ireland | IMBc | Endorses MHRA warning for Ireland |
| 2004, February | U.S.  | FDA    | Commissioned advisory committee |
| 2004, October | U.S. | FDA    | Issued black box warning relating to all anti-depressants <18 s |
| 2005, August | Europe | EMEA  | Issued warning against SSRIs in <18 s |
| 2005, November | Ireland | IMB | Reissued warning and updated label guidelines |
| 2007, May    | U.S.    | FDA    | Increased age of risk of SSRIs to 24 years |
| 2008, September | Ireland | IMB  | Warnings adapted up to age 25 |

*Medicines & Health Regulatory Agency Food & Drug Administration Irish Medicines Board European Medicines Agency*
Reimbursement Services (PCRS). The database contains basic demographic information and details of dispensed medications (coded using WHO’s Anatomical Therapeutic Chemical (ATC) classification) for each individual on the GMS scheme. The scheme is means tested and provides free health services to those who are unable to afford them. It represents approximately 28 % of Irish children but over-represents socially deprived populations. Data is freely available but with the necessary confidentiality agreements. Permission was given by the data controller to use the GMS dataset if anonymised and analysed at group level. Therefore, it was unnecessary to seek specific ethical approval for this study.

All anti-depressant medication prescriptions (N06A; classified according to the ATC classification system) were extracted from the GMS database for children aged 0–15 years inclusive for the years 2002–2011.

Data analysis
The yearly prevalence of anti-depressants per 1000 GMS population and associated 95 % confidence intervals for children aged 0–15 years were calculated as a proportion of all eligible children (0–15 years) entitled to free health services, as identified from the annual reports produced by the PCRS. The prevalence per 1000 GMS eligible population and associated 95 % confidence intervals (CIs) were also calculated across years (2002–2011), age groups (0–4 years, 5–11 years and 12–15 years) and gender.

A negative binomial regression model was used to determine trends in prevalence. The log of the GMS population was used as the offset term and year, age group, gender and all possible interactions between these variables were included as fixed effects in the model. The Bonferroni method was used to control the overall Type I error rate in making multiple comparisons of means and p-values <0.05 were deemed significant.

Data analyses was performed using Stata version 11 (StataCorp, College Station, TX, USA) and SAS version 9.3 (SAS Institute Inc. Cary, NC, USA).

Comparison studies
Comparison studies, examining the prevalence of anti-depressants in paediatric populations, were identified from a search of published literature from 1995 – 2013. Articles were included if they reported the prevalence of anti-depressants in a community setting and provided overall prevalence. Studies which reported overall percentage prevalence were transformed to per 1000 population to facilitate comparison.

Results
Population sample
During the study period, January 2002 to December 2011, the number of children ≤15 years in Ireland, as identified from the HSE-PCRS pharmacy database, ranged between 188,833 and 311,579. On average, 51 % of the study population were male and 49 % were female.

Prescribing trends
Table 2 shows the prevalence of anti-depressants for 2002–2011. In 2002, 4.74/1000 population (95 % CI: 4.47-5.01) received at least one anti-depressant medication prescription and this decreased yearly to 2.61/1000 population (95 % CI: 2.43-2.80) in 2008. Between 2008 and 2011 the prevalence fluctuated slightly.

During the study period the prevalence of SSRIs was much higher than non-SSRIs (Fig. 1). There were no significant differences in the prevalence of SSRIs between 2002 and 2003. However, a significant decrease was seen between 2003 and 2004, and 2003 and 2005; the period directly following the IMB warning. Since 2005, the prevalence of SSRIs has remained relatively stable.

Fluoxetine was the most frequently prescribed anti-depressant (Fig. 2), and although no significant differences were seen, the prevalence of fluoxetine increased between 2002 and 2011. Over the study period a decrease in the prevalence of contra-indicated anti-depressants was seen. The prevalence of paroxetine decreased significantly from 1.00/1000 population (95 % CI: 0.88-1.13) in 2002 to 0.03/1000 population (95 % CI: 0.02-0.05) in 2011. Significant decreases were observed yearly from 2002 through to 2007. From 2007 onwards, the prevalence stabilised. The prevalence of citalopram also decreased significantly over the study period from 0.87/1000 population (95 % CI: 0.75-0.98) in 2002 to 0.19/1000 population (95 % CI: 0.14-0.23) in 2011. The prevalence of sertraline and escitalopram, after its introduction to the market in 2002,

Table 2 Prevalence and 95 % confidence intervals of anti-depressants to children aged 0–15 years from 2002–2011

| Year | Prevalence per 1,000 GMS population (95 % confidence interval) |
|------|---------------------------------------------------------------|
| 2002 | 4.74 (4.47-5.01)                                             |
| 2003 | 4.33 (4.07-4.59)                                             |
| 2004 | 3.86 (3.62-4.11)                                             |
| 2005 | 3.51 (3.27-3.74)                                             |
| 2006 | 3.09 (2.87-3.30)                                             |
| 2007 | 2.72 (2.52-2.91)                                             |
| 2008 | 2.61 (2.43-2.80)                                             |
| 2009 | 2.71 (2.54-2.89)                                             |
| 2010 | 2.63 (2.47-2.80)                                             |
| 2011 | 2.86 (2.69-3.03)                                             |
fluctuated over the study period (Fig. 2). For sertraline, significant decreases between 2004 and 2006, and 2004 and 2007 were observed.

Gender and Age

Figure 3 shows the prevalence of anti-depressants for all years for males and females and all age groups (0–4 years, 5–11 years and 12–15 years). The fixed interactions year × gender × age group \((p = 0.93)\) and year × gender \((p = 0.35)\) were not significant while the interactions age group × year \((p < 0.0001)\) and age group × gender \((p < 0.0001)\) were significant. This means that the effect of age group on the prevalence of anti-depressants differed over years and differed for males and females also.

The least square means and \(t\)-tests for the difference in prevalence of anti-depressants between age groups for gender and years showed that significant differences existed between males and females for all age groups whereby males had higher prevalences at 0–4, and 5–11 age groups. Females had higher rates in the 12–15 year age group. Additionally, for all years, significantly higher prevalences were seen for the 12–15 year age group compared to the 0–4 year, and the 5–11 year groups.

**Fig. 1** Prevalence of SSRIs (N06AB) vs non-SSRIs (N06AA, N06AF, N06AG, N06AX) per 1000 GMS population aged 0–15 years old from 2002 to 2011

**Fig. 2** Prevalence of SSRIs per 1000 GMS population aged 0–15 years old from 2002 to 2011 (including when warnings were introduced)
Overall significantly higher prevalences were seen for the 5–11 year age group compared to the 0–4 year group for 2002, 2004, 2005 and 2006 only.

**Comparison studies**

Studies examining the overall prevalence and incidence of anti-depressants in paediatric populations in a community setting were identified (Table 3). Studies from Netherlands [21], the US [22], UK [11], Germany [23], and Denmark [24] were included.

The overall prevalence of anti-depressants for the study period was 3.3/1000 population. Only one country reported a higher overall prevalence, the US study conducted between 2002 and 2005 (8.77/1000 population) [22]. Table 3 shows that the prevalence of anti-depressants in paediatrics varies substantially with Ireland ranked higher than the majority of comparison countries. However, there are differences across the different studies in terms of age groups, sample size and year the data were assessed.

**Discussion**

The study observed that SSRI prescription rates reduced significantly following the introduction of the IMB warning. It showed that paroxetine rates reduced from 2002 onwards, which may indicate the influence of media coverage on Irish prescribing. Results show that adolescent girls are more likely to receive a prescription of anti-depressants than adolescent boys and the overall prevalence of anti-depressants in 0–15 year olds in Ireland lies close to the median value in comparison to international studies.

An overall reduction in the prevalence of SSRIs and all anti-depressants in children over the study period was seen. These reductions appear to be influenced by the IMB and MHRA regulatory recommendations of 2003. Higher rates of fluoxetine prescribing further supports

| Study (publication year) | Country (year data represents) | Sample Size | Age | Overall Rate of Anti-depressant Prescribing (per 1000) | Setting |
|--------------------------|--------------------------------|-------------|-----|------------------------------------------------------|---------|
| Dorks (2013) [23]        | Germany (2004–2006)            | 2 599 685   | 0–17| 1.7/1000                                             | Pharmaco-epidemiology database |
| Volkers (2007) [24]      | Netherlands (2001–2005)        | 350 000     | 0–17| 2.2/1000                                             | Information Network of General Practice |
| Wijlaars (2012) [12]     | UK (1995–2009)                 | 1 502 753   | 0–17| 3.6/1000                                             | UK primary care database |
| Parkinson (2012) [25]    | US (2002–2005)                 | 32 111      | 0–17| 8.77/1000                                            | Medical Expenditure Panel survey |
| Steinhausen (2014) [26]  | Denmark (1996–2010)            | 10 590     | 0–17| 1.6/1000                                             | National Patient Database |
| GMS data                 | Ireland (2002 – 2011)          | 311 579     | 0–15| 3.3/1000                                             | Primary care reimbursement service pharmacy claims |
this. The MHRA deemed fluoxetine an acceptable treatment of MDD in children, a stance which was adopted by the IMB. Interestingly, the prevalence of fluoxetine increases from 2002 to 2011. This suggests that while the prevalence of SSRIs decreased over time, the prevalence of fluoxetine, in Ireland, was not affected by the general black box warning placed on all SSRIs by the FDA.

In addition to an overall reduction in the prevalence of anti-depressants, the study observed a significant reduction in the prevalence of contra-indicated anti-depressants - paroxetine and citalopram and to some extent sertraline. This decrease, coupled with the increase of fluoxetine prescribing, suggests a possible link between the IMB warning and prescription practices. The decrease in citalopram began in 2003, the year the warning was issued. The decline in paroxetine use was more pronounced than the other SSRIs and began in 2002, prior to the IMB warnings [25].

Since 2005 the prevalence of SSRIs in children on the GMS has remained relatively stable (2.1/1000 population). While not significant, the prevalence increased in the latter part of the study period. This may indicate that concerns about the risks associated with SSRIs have dissipated in recent years. This may be due to contradictions that exist in recent literature regarding the safety and efficacy of SSRIs. For example, some studies report no increased risk of suicidality following SSRI prescriptions in childhood [26] and others suggest that a relationship exists between decreases in the prevalence of SSRIs and increases in suicide behaviour among young people [27]. Contrary to this view a recent review of published and unpublished SSRI research revealed significant increases in suicidal behaviour in children taking contra-indicated SSRIs [12–14, 28, 29].

Age and gender analysis revealed that before adolescence (<12 years of age), boys were more likely to be prescribed an anti-depressant than girls. This trend reversed after age 12 where significantly more girls received an anti-depressant prescription than boys. This finding is in line with previous research, whereby prepubescent boys show higher rates of anti-depressant prescriptions than prepubescent girls [11], and adolescent girls show higher rates of anti-depressant prescriptions than adolescent boys [11, 21, 24]. Research shows that girls aged 3–13 years are less likely than boys to be diagnosed with major depression and girls age 12–17 are more likely to meet the diagnostic criteria of major depression than boys [11]. Age trends reveal that older children (12–15 age groups) are more likely to be prescribed an anti-depressant than both younger age groups. This is consistent with previous research which shows that the rate of anti-depressant and overall psychotropic prescriptions increases with age [18, 27].

The prevalence of anti-depressants in the current study are similar in size and trend to those found in the UK primary care database which examined prevalence from 1995 to 2009 [11]. They found a reduction of SSRI rates following the FDA warning. However, of the contra-indicated SSRIs only paroxetine showed a significant decrease following 2003; citalopram and sertraline were not affected. This difference in contra-indicated prescription trends may be a consequence of methodological differences between our study and the UK study. Our study examined year on year prescription rates, whereas the UK study looked at 3 time periods (1995 – 2002, 2003–2005, and 2006–2009).

While the overall prevalence for the current study was similar to the UK, it was higher than Germany, the Netherlands and Denmark. Denmark showed the smallest overall prevalence and the Danish prescribing trends did not seem to be affected by the FDA warning. The rates in the US study were twice the rate of our study, which is in line with previous research findings [17]. The differences in prescription trends may be due to high levels of heterogeneity between the studies, cultural variation in prescription practices and differences in the availability of other treatments options [28].

Limitations
The HSE-PCRS GMS pharmacy claims database represents approximately one-third of Irish children and over-represents more socially disadvantaged children in the Irish population. This may result in an over-estimation of the true trends in the prevalence of anti-depressants, given that children from lower socioeconomic backgrounds are more likely to be prescribed a psychotropic medication [29, 30] and are at greater risk of depression [11] and anxiety related disorders [31]. Direct comparison of international prevalence for low socioeconomic populations was limited; however studies that have included deprivation as an indicator of prevalence show that as deprivation increases the prevalence of anti-depressants increases also [11].

The GMS data set does not collect information about the indication for prescriptions or about the setting in which the prescription was initiated (e.g. primary care, hospital or specialist setting). In addition, there are no national rates of childhood depression available in Ireland to compare current prescription rates to. This lack of diagnostic information makes it difficult to know whether the current rates reflect treatment of depression, or other conditions (obsessive compulsive disorder (OCD) or anxiety). We know that cultural differences exist in terms of what indications anti-depressants are prescribed for. For example, in the US they are often prescribed for depression and ADHD, whereas in Europe OCD and depression are most likely to receive an anti-
depressant prescription [17]. The current data does not allow us to explore the indications for which antidepressants are most commonly prescribed in Irish children. Furthermore, there is no data on dispensing and treatment compliance; hence the current rate may not accurately reflect actual anti-depressant use.

Conclusions
After 2003, a significant decrease in the prevalence of SSRIs in children, particularly paroxetine and citralopram, was found. The prevalence of fluoxetine remained stable and increased from 2002 to 2011. The direction and timing of these trends suggest that medical practitioners followed the FDA and CSM advice, although the earlier reduction of paroxetine would suggest that the negative media attention had an influence on prevalence, though it is unknown whether this effect was patient or practitioner driven.

Abbreviations
GMS: General Medical Services; SSRIs: Selective serotonin reuptake inhibitors; RCT: Randomised controlled trials; FDA: Food and Drug Administration; MDD: Major depressive disorder; MHRA: Medicines and Health Regulatory Agency; IMB: Irish Medical Board; ATC: Anatomical Therapeutic Chemical.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
All the authors contributed to the development of this manuscript. TF, KB, NM, DK and UR jointly conceived the study. FB designed and implemented the analytical model with contributions from KO and NM. KO prepared the manuscript. KB, TF, FB and KO edited the manuscript. All authors read and approved the final manuscript.

Authors’ information
The principle investigator is Professor Tom Fahey from the HRB Centre for Primary Care Research, Division of Population Health Sciences, Royal College of Surgeons in Ireland, 123 St Stephens Green, Dublin 2.

Acknowledgements
The authors acknowledge the HSE-PCRS for supplying the data and the HRB-PCRS for conducting the study. The authors also acknowledge the HSE-PCRS for the use of the practice research database. The principle investigator is Professor Tom Fahey from the HRB Centre for Primary Care Research, Division of Population Health Sciences, Royal College of Surgeons in Ireland, 123 St Stephens Green, Dublin 2, Ireland.

Received: 6 June 2014 Accepted: 26 August 2015
Published online: 11 September 2015

References
1. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013;34:119–38. PMC. Web. 13 Apr. 2015.
2. Kessler RC, Chiu W, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005;62(6):617–27.
3. Cheung AH, Emslie GJ, Mayes TL. The use of anti-depressants to treat depression in children and adolescents. Can Med Assoc J. 2006;174(2):193–200.
4. Cox Georgina R, Callahan P, Churchill R, Hunot V, Merry Sally N, Parker Alexandra G, et al. Psychological therapies versus anti-depressant medication, alone and in combination for depression in children and adolescents. Cochrane Database of Systematic Reviews [Internet]. 2012; (11). Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008324.pub2/abstract
5. Jane Costello E, Erkanli A, Angold A. Is there an epidemic of child or adolescent depression? J Child Psychology and Psychiatry. 2006;47(12):1263–71.
6. Dean AJ, McDermott BM, Marshall RT. Psychotropic medication utilization in a child and adolescent mental health service. J Child Adolesc Psychopharmacol. 2006;16(3):273–85. PubMed Epub 2006/06/14. eng.
7. Murray ML, de Vries CS, Wong ICK. A drug utilisation study of anti-depressants in children and adolescents using the general practice research database. Arch Dis Child. 2004;89(12):1098–102.
8. Vitello B. Pharmacoepidemiology and pediatric psychopharmacology research. J Child Adolesc Psychopharmacol. 2005;15:10–1. doi:10.1089/ cap.2005.15.10. PubMed PMID.
9. Zito J, Tobin H, de Jong-van den L, Fegert J, Safer D, Janhsen K, et al. Anti-depressant prevalence for youths: a multi-national comparison. Pharmacoepidemiol Drug Saf. 2006;15:793–8. doi:10.1002/pds.1254. PubMed PMID.
10. Trindade E, Menon D, Topfer LA, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ. 1998;159:1245–52.
11. Kelder MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birnhaier B, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Academy of Child & Adolescent Psychiatry. 2001;40(7):762–72.
12. Wijlaars LPM, Nazareth I, Petersen T. Trends in depression and anti-depressant prescribing in children and adolescents: a cohort study in The Health Improvement Network (THIN). PLoS One. 2012;7(3):e33181.
13. Hammad TA. Review and evaluation of clinical data. BMJ. 2003;326(7402):1282. Available at http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-0635b1-10-TAB08-Hammads-Review.pdf (last accessed 24 April 2014). Waechter F. Paroxetine must not be given to patients under 18.
14. Whitington CJ, Kendall T, Fonagy P, Cortelli D, Cottgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. The Lancet. 2004;363(9418):1341–5.
15. Mann JJ, Emslie G, Baldessarini RJ, Beasley W, Fawcett JA, Goodwin FK, et al. ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacol. 2006;31(3):473–92. PubMed Epub 2005/12/02. eng.
16. Schirm E, Tobin H, Zito J, de Jong-van den Berg L. Psychotropic medication in children: a study from the Netherlands. Pediatrics. 2001;108:E25. doi:10.1542/peds.108.2.e25. PubMed PMID.
17. Zito J. Psychopharmacology ASCC. Pharmacoepidemiology: recent findings and challenges for child and adolescent psychopharmacology. J Clin Psychiatry. 2007;68:966–7. doi:10.4088/JCP.v68n0622. PubMed PMID.
18. Zito J, Safer D, Berg L, Janhsen K, Fegert J, Gardner J, et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health. 2008;25:36–32. doi:10.1186/1753-2002-2-26. PubMed PMID.
19. Gyllenberg D, Sourander A. Psychotropic drug and polypharmacy use among adolescents and young adults: findings from the Finnish 1981 Nationwide Birth Cohort Study. Nord J Psychiatry. 2012;66(5):336–42. PubMed Epub 2012/01/04. eng.
20. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2012. Oslo, 2011. ISBN: 978-82-9802-477-6.
21. Hugtenburg JG, Heerdink ER, Egberts AC. Increased psychotropic drug consumption by children in the Netherlands during 1995–2001 is caused by increased use of methylphenidate by boys. Eur J Clin Pharmacol. 2004;60(5):377–9. English.
22. Mittal M, Harrison DE, Miller MJ, Brahm NC. National anti-depressant prescribing in children and adolescents with mental health disorders after an FDA boxed warning. Research in social & administrative pharmacy. RASP. 2013 Nov 20. PubMed Epub 2013/12/21. eng.
23. Dörks M, Langner I, Dittmann U, Timmer A, Garbe E. Anti-depressant drug use and off-label prescribing in children and adolescents in Germany: results from a large population-based cohort study. Eur Child Adolesc Psychiatry. 2013;22(8):511–8. English.
24. Volkers AC, Heerdink ER, van Dijk L. Anti-depressant use and off-label prescribing in children and adolescents in Dutch general practice (2001–2005). Pharmacoepidemiol Drug Saf. 2007;16(9):1054–62.

25. Parkinson K, Price J, Simon K, Tennyson S. The influence of FDA advisory information and black box warnings on individual use of prescription anti-depressants. Rev Econ Household. 2012 2012/05/15;1–20. English.

26. Steinhausen HC, Biggaard C. Nationwide time trends in dispensed prescriptions of psychotropic medication for children and adolescents in Denmark. Acta Psychiatr Scand. 2014;129(3):221–31. PubMed Epub 2013/06/07. eng.

27. Pj C. TV: panorama: “the secrets of seroxat”. BMJ. 2002.

28. Jick H, Kaye JA, Jick SS. Anti-depressants and the risk of suicidal behaviors. IAMA. 2004/03/27;338–43. PubMed Epub 2004/07/22. eng.

29. Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev. 2012;11:CD004851. doi:10.1002/14651858.CD004851.pub3.

30. Suicide trends among youths and young adults aged 10–24 years—United States, 1990–2004. MMWR Morbidity and mortality weekly report. 2007;756(35):905–8. PubMed Epub 2007/09/07. Eng.

31. Vitello B. An international perspective on pediatric psychopharmacology1. Int Rev Psychiatry. 2008;20(2):121–6.